26-05-2011: 4-Antibody AG announced the signing of a multi-target research alliance with the Ludwig Institute for Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are important in the suppression of the immune response in cancer. Financial details were not disclosed.
4-Antibody will use its high throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibodies against a series of disease targets with key roles in the suppression of immune responses in cancer patients. The Ludwig Institute will then take these antibody drugs into early clinical testing with the specific clinical goal of demonstrating the feasibility of reversing immunosuppression in cancer. At the point at which the programmes have achieved agreed technical milestones, 4-Antibody will seek pharmaceutical partnerships for the emerging product opportunities.
Dr Robert Burns, CEO of 4-Antibody, commented: “For nearly three decades the Ludwig Institute has focused its worldwide clinical research efforts in cancer immunology and has built an extraordinary expertise in the monitoring of patient immunological responses in cancer immunotherapy settings. The concept of reversing tolerance in cancer has been clinically validated with the recent approval of an anti-CTLA4 antibody. We intend to target parallel pathways in our programme with LICR through its research branch at the Memorial Sloan Kettering Cancer Center in New York where we expect eventual clinical trials to take place.”
Andrew Simpson, PhD, LICR’s Scientific Director, added: “The Ludwig Institute has a long history of conducting innovative clinical research in the field of cancer immunotherapy. The combination of 4-Antibody’s high throughput Retrocyte Display® technology and its ability to rapidly generate panels of novel fully human full length therapeutic antibodies will speed our research into the identification of clinical strategies to selective interfere with the immunomodulatory mechanisms that lie at the heart of tumours’ ability to evade otherwise effective immune responses – a major goal for the improved treatment of cancer.”
A Melbourne-based research team has discovered a genetic defect that can halt cell growth and force cells into a death-evading survival state.
The finding has revealed an important mechanism controlling the growth of rapidly-dividing cells that may ultimately lead to the development of new ... more
Malignant melanoma is the most aggressive type of skin cancer. In more than 50 percent of affected patients a particular mutation plays an important role. As the life span of the patients carrying the mutation can be significantly extended by novel drugs, it is very important to identify th ... more
The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at ... more
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institu ... more
4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ... more
4-Antibody AG announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment.
4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term co ... more
4-Antibody AG announced the signing of a multi-target research alliance with the Ludwig Institute for Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are important in the suppress ... more
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to pharmaceutical partners and is also using it to generate a proprietary pipeline of antibody therapeutic drugs. 4-Antibody is ... more